EP. 11: Results of RxPONDER in HR+ Breast Cancer
Dr Andrew Seidman reacts to outcomes of the RxPONDER trial of chemotherapy use in women with HR-positive breast cancer at low risk of recurrence.
EP. 12: Rationale for Ovarian Suppression in HR+ Breast Cancer
During a discussion regarding data demonstrated by the RxPONDER trial in HR-positive breast cancer, breast oncologists consider when ovarian suppression is most appropriate and for whom.
EP. 13: Updated Results of MonarchE in HR+ Breast Cancer
Dr Sara Tolaney comments on recent updates of the monarchE trial of abemaciclib and adjuvant endocrine therapy for high-risk early stage breast cancer as presented at SABCS 2020.
EP. 14: The PENELOPE-B Study in HR+ Breast Cancer
Dr Massimo Cristofanilli, of the Feinberg School of Medicine, describes the PENELOPE-B study of palbociclib and endocrine therapy for patients with HR-positive breast cancer at high risk of relapse after neoadjuvant chemotherapy.
EP. 15: The PRIME II Study in HR+ Breast Cancer
Andrew Seidman, MD, comments on results of the PRIME II study presented at SABCS and the appropriateness for radiation therapy in certain patient populations with HR-positive breast cancer.
EP. 16: Case Discussion 2: Systemic Therapy for ER+, PR+, HER2- Breast Cancer
Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.
EP. 17: Treatment Advances in HR+ Breast Cancer
A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.